Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.855
-3.095 (-1.15%)
Market Cap: 34.29 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,063.42
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2019 / 02:30PM GMT
Release Date Price:
$70.4
(-0.56%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to introduce Barry Greene, the President at Alnylam; and Manmeet Soni, the CFO at Alnylam. Thanks so much for joining us today. We're going to have a fireside chat, so pretty informal conversation.
Barry E. Greene
Alnylam Pharmaceuticals, Inc. - President
Sounds good.
Questions & Answers
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Maybe if you just want to give us an intro to Alnylam and give us an update on the company.
Barry E. Greene
Alnylam Pharmaceuticals, Inc. - President
So how long do we have? Maury, thank you for having us and thanks to the organizers for having us as well. It's really a pleasure to be here.
Alnylam is the leading RNAi therapeutic company, and the company is about 17 years old. And we started Alnylam
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot